Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by Transperanceon Jul 04, 2021 5:20am
216 Views
Post# 33490382

RE:RE:Trial and error

RE:RE:Trial and error

True about the board people, one should diversify when choosing board members in order to cover multiple competence areas to the benefit of the company. Furthermore, the board should govern and steer the company in the right direction. The CEO should report performance to the board on a regular, quarterly, basis. My view is that the board people in Sirona are very much names on a paper and that Howard is running the company very much as he likes without much board interference and governance towards long term goals. The antiviral excursion is an example of such lack of governance. The company must not cover activities outside focus areas, even if sponsored with government funds. They should focus on the essentials in line with the business plan.

 

In all small organisations, there is a risk related to dependency on key personnel. There is a risk, basically, in all core positions of Sirona, if it would turn out that someone in the management group is not doing a professional job. In the case of Howard the risk is very much dependent on how well he knows himself. I just know Howard through the Youtube interviews, but I am sure that he has plenty of compentencies, even though he has also shown a lack of basic industry and business understanding, as stated earlier. 

 

As I understood it, the former CEO, Neil, has negotiation skills (he is no MD). Whether Howard himself has these skills remains to be seen. Perhaps it would be good for the company to hire a negotiator when negotiating terms with majors. From my experience, MDs are not necessarily sound negotiators, typically they have other competencies. 

<< Previous
Bullboard Posts
Next >>